Labcorp Holdings annual ebitda
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Labcorp Holdings EBITDA Growth & History (LH)
Labcorp Holdings's calculated EBITDA was $2.07B for fiscal 2025.
View full Labcorp Holdings company overviewLabcorp Holdings annual ebitda history
| Fiscal year | Period ended | EBITDA | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $2.07B | $335.6M | +19.40% |
| 2024 | 2024-12-31 | $1.73B | $427.3M | +32.80% |
| 2023 | 2023-12-31 | $1.30B | −$670.8M | −33.99% |
| 2022 | 2022-12-31 | $1.97B | −$1.65B | −45.56% |
| 2021 | 2021-12-31 | $3.63B | $555.5M | +18.09% |
| 2020 | 2020-12-31 | $3.07B | $1.16B | +60.96% |
| 2019 | 2019-12-31 | $1.91B | $29.6M | +1.58% |
| 2018 | 2018-12-31 | $1.88B | $39.4M | +2.14% |
| 2017 | 2017-12-31 | $1.84B | $68.6M | +3.88% |
| 2016 | 2016-12-31 | $1.77B | $315.2M | +21.67% |
| 2015 | 2015-12-31 | $1.45B | $298.7M | +25.84% |
| 2014 | 2014-12-31 | $1.16B | −$65.1M | −5.33% |
| 2013 | 2013-12-31 | $1.22B | −$32.3M | −2.58% |
| 2012 | 2012-12-31 | $1.25B | $73.5M | +6.23% |
| 2011 | 2011-12-31 | $1.18B | −$2.6M | −0.22% |
| 2010 | 2010-12-31 | $1.18B | $51.4M | +4.54% |
| 2009 | 2009-12-31 | $1.13B | $108.4M | +10.60% |
| 2008 | 2008-12-31 | $1.02B | $82.8M | +8.81% |
| 2007 | 2007-12-31 | $939.8M | — | — |
Labcorp Holdings quarterly ebitda
Q3.08
Q1.09
Q2.09
Q3.09
Q4.09
Q1.10
Q2.10
Q3.10
Q4.10
Q1.11
Q2.11
Q3.11
Q4.11
Q1.12
Q2.12
Q3.12
Q4.12
Q1.13
Q2.13
Q3.13
Q4.13
Q1.14
Q3.14
Q1.15
Q2.15
Q3.15
Q4.15
Q1.16
Q2.16
Q3.16
Q4.16
Q1.17
Q2.17
Q3.17
Q4.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | EBITDA | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $630.6M | $65.8M | +11.65% |
| Q1 2026 | 2026-03-31 | $554.1M | $61.3M | +12.44% |
| Q4 2025 | 2025-12-31 | $440.6M | $53.5M | +13.82% |
| Q3 2025 | 2025-09-30 | $567.6M | $152.0M | +36.57% |
| Q2 2025 | 2025-06-30 | $564.8M | $113.1M | +25.04% |
| Q1 2025 | 2025-03-31 | $492.8M | $17.0M | +3.57% |
| Q4 2024 | 2024-12-31 | $387.1M | $363.5M | +1540.25% |
| Q3 2024 | 2024-09-30 | $415.6M | $17.4M | +4.37% |
| Q2 2024 | 2024-06-30 | $451.7M | $42.5M | +10.39% |
| Q1 2024 | 2024-03-31 | $475.8M | $3.9M | +0.83% |
| Q4 2023 | 2023-12-31 | $23.6M | −$52.6M | −69.03% |
| Q3 2023 | 2023-09-30 | $398.2M | −$109.9M | −21.63% |
| Q2 2023 | 2023-06-30 | $409.2M | −$130.8M | −24.22% |
| Q1 2023 | 2023-03-31 | $471.9M | −$377.5M | −44.44% |
| Q4 2022 | 2022-12-31 | $76.2M | −$463.4M | −85.88% |
| Q3 2022 | 2022-09-30 | $508.1M | −$444.9M | −46.68% |
| Q2 2022 | 2022-06-30 | $540.0M | −$351.2M | −39.41% |
| Q1 2022 | 2022-03-31 | $849.4M | −$392.4M | −31.60% |
| Q4 2021 | 2021-12-31 | $539.6M | −$937.5M | −63.47% |
| Q3 2021 | 2021-09-30 | $953.0M | −$246.4M | −20.54% |
| Q2 2021 | 2021-06-30 | $891.2M | $449.6M | +101.81% |
| Q1 2021 | 2021-03-31 | $1.24B | $1.29B | — |
| Q4 2020 | 2020-12-31 | $1.48B | $984.9M | +200.10% |
| Q3 2020 | 2020-09-30 | $1.20B | $715.2M | +147.71% |
| Q2 2020 | 2020-06-30 | $441.6M | −$35.7M | −7.48% |
| Q1 2020 | 2020-03-31 | −$48.0M | −$501.7M | — |
| Q4 2019 | 2019-12-31 | $492.2M | $46.8M | +10.51% |
| Q3 2019 | 2019-09-30 | $484.2M | $7.7M | +1.62% |
| Q2 2019 | 2019-06-30 | $477.3M | −$30.4M | −5.99% |
| Q1 2019 | 2019-03-31 | $453.7M | $5.5M | +1.23% |
| Q4 2018 | 2018-12-31 | $445.4M | −$30.2M | −6.35% |
| Q3 2018 | 2018-09-30 | $476.5M | $16.7M | +3.63% |
| Q2 2018 | 2018-06-30 | $507.7M | $50.9M | +11.14% |
| Q1 2018 | 2018-03-31 | $448.2M | $2.0M | +0.45% |
| Q4 2017 | 2017-12-31 | $475.6M | $63.7M | +15.46% |
| Q3 2017 | 2017-09-30 | $459.8M | $14.7M | +3.30% |
| Q2 2017 | 2017-06-30 | $456.8M | −$34.1M | −6.95% |
| Q1 2017 | 2017-03-31 | $446.2M | $24.3M | +5.76% |
| Q4 2016 | 2016-12-31 | $411.9M | $60.6M | +17.25% |
| Q3 2016 | 2016-09-30 | $445.1M | $17.4M | +4.07% |
| Q2 2016 | 2016-06-30 | $490.9M | $50.3M | +11.42% |
| Q1 2016 | 2016-03-31 | $421.9M | $186.9M | +79.53% |
| Q4 2015 | 2015-12-31 | $351.3M | — | — |
| Q3 2015 | 2015-09-30 | $427.7M | $127.8M | +42.61% |
| Q2 2015 | 2015-06-30 | $440.6M | — | — |
| Q1 2015 | 2015-03-31 | $235.0M | −$914.8M | −79.56% |
| Q3 2014 | 2014-09-30 | $299.9M | −$2.6M | −0.86% |
| Q1 2014 | 2014-03-31 | $1.15B | $832.3M | +262.14% |
| Q4 2013 | 2013-12-31 | $274.8M | $100,000 | +0.04% |
| Q3 2013 | 2013-09-30 | $302.5M | −$200,000 | −0.07% |
| Q2 2013 | 2013-06-30 | $326.2M | −$5.9M | −1.78% |
| Q1 2013 | 2013-03-31 | $317.5M | −$26.3M | −7.65% |
| Q4 2012 | 2012-12-31 | $274.7M | −$30.6M | −10.02% |
| Q3 2012 | 2012-09-30 | $302.7M | $5.6M | +1.88% |
| Q2 2012 | 2012-06-30 | $332.1M | $48.6M | +17.14% |
| Q1 2012 | 2012-03-31 | $343.8M | $49.9M | +16.98% |
| Q4 2011 | 2011-12-31 | $305.3M | $13.6M | +4.66% |
| Q3 2011 | 2011-09-30 | $297.1M | $11.2M | +3.92% |
| Q2 2011 | 2011-06-30 | $283.5M | −$37.1M | −11.57% |
| Q1 2011 | 2011-03-31 | $293.9M | $9.7M | +3.41% |
| Q4 2010 | 2010-12-31 | $291.7M | $26.1M | +9.83% |
| Q3 2010 | 2010-09-30 | $285.9M | $1.5M | +0.53% |
| Q2 2010 | 2010-06-30 | $320.6M | $27.4M | +9.35% |
| Q1 2010 | 2010-03-31 | $284.2M | −$3.6M | −1.25% |
| Q4 2009 | 2009-12-31 | $265.6M | — | — |
| Q3 2009 | 2009-09-30 | $284.4M | $37.0M | +14.96% |
| Q2 2009 | 2009-06-30 | $293.2M | — | — |
| Q1 2009 | 2009-03-31 | $287.8M | — | — |
| Q3 2008 | 2008-09-30 | $247.4M | — | — |
Labcorp Holdings ebitda trends
Over the last five fiscal years, Labcorp Holdings's ebitda decreased from $3.07B to $2.07B, a change of −$1.00B. The latest reported quarter, Q2 2026, shows $630.6M.
About the metric
What EBITDA means
EBITDA is a measure of operating performance before interest, taxes, depreciation, and amortization. It can help compare operating results, but it is not a substitute for cash flow or GAAP net income.
Calculation and source
How TickerStat calculates EBITDA
TickerStat calculates EBITDA as operating income plus reported depreciation and amortization for aligned fiscal periods. It is calculated data, not adjusted EBITDA or company guidance. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Labcorp Holdings source filings ↗Community posts
Labcorp sets new medium-term growth targets and reaffirms its annual outlook
Labcorp ($LH) set medium-term targets for annual revenue growth of 5–8% and adjusted earnings-per-share growth of 8.5–11.5% through 2029. The company also reaffirmed its existing 2026 guidance. The new framework describes the performance ma ...
Labcorp acquires MLM Medical Labs to expand clinical-trial services
Labcorp ($LH) acquired MLM Medical Labs, adding central and specialty laboratory operations in the United States, Germany and South Africa. The company said the purchase expands its biomarker-testing capabilities and improves its ability to ...
